154 related articles for article (PubMed ID: 24413723)
1. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Park JW; Kang SH; Do JY
Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
[TBL] [Abstract][Full Text] [Related]
2. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients.
Do JY; Kim YL; Park JW; Cho KH; Kim TW; Yoon KW; Kim CD; Park SH; Han JH; Song IH
Perit Dial Int; 2005 Feb; 25 Suppl 3():S22-5. PubMed ID: 16048250
[TBL] [Abstract][Full Text] [Related]
3. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
4. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
[TBL] [Abstract][Full Text] [Related]
6. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
7. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
8. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
9. Exfoliated mesothelial cell and CA-125 in automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD) patients.
Kanjanabuch T; Puttipittayathorn N; Leelahavanichkul A; Lieusuwan S; Katavetin P; Mahatanan N; Sriudom K; Chirananthavat T; Thongbor N; Eiam-Ong S
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S119-25. PubMed ID: 22043578
[TBL] [Abstract][Full Text] [Related]
10. Re: effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Ahmadi F
Iran J Kidney Dis; 2014 Mar; 8(2):158-60. PubMed ID: 24685741
[No Abstract] [Full Text] [Related]
11. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
[TBL] [Abstract][Full Text] [Related]
12. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
13. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
[TBL] [Abstract][Full Text] [Related]
14. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
Haag-Weber M; Krämer R; Haake R; Islam MS; Prischl F; Haug U; Nabut JL; Deppisch R;
Nephrol Dial Transplant; 2010 Jul; 25(7):2288-96. PubMed ID: 20197284
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
16. Biocompatible peritoneal dialysis solution preserves residual renal function.
Kim S; Oh KH; Oh J; Kim SJ; Chung W; Song YR; Na KY; Oh YK; Ahn C; Kim SG; Tan KC
Am J Nephrol; 2012; 36(4):305-16. PubMed ID: 23007025
[TBL] [Abstract][Full Text] [Related]
17. Overnight mesothelial cell exfoliation: a magic tool for predicting future ultrafiltration failure in patients on continuous ambulatory peritoneal dialysis.
Kanjanabuch T; Siribamrungwong M; Khunprakant R; Kanjanabuch S; Jeungsmarn P; Achavanuntakul B; Pongpirul K; Park MS; Tungsanga K; Eiam-Ong S
Perit Dial Int; 2008 Jun; 28 Suppl 3():S107-13. PubMed ID: 18552238
[TBL] [Abstract][Full Text] [Related]
18. Time to reconsider saline as the ideal rinsing solution during abdominal surgery.
Połubinska A; Winckiewicz M; Staniszewski R; Breborowicz A; Oreopoulos DG
Am J Surg; 2006 Sep; 192(3):281-5. PubMed ID: 16920418
[TBL] [Abstract][Full Text] [Related]
19. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content.
Schmitt CP; von Heyl D; Rieger S; Arbeiter K; Bonzel KE; Fischbach M; Misselwitz J; Pieper AK; Schaefer F;
Nephrol Dial Transplant; 2007 Jul; 22(7):2038-44. PubMed ID: 17420168
[TBL] [Abstract][Full Text] [Related]
20. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
Fusshoeller A; Plail M; Grabensee B; Plum J
Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]